Merck

Trending/Merck

Tumor Size is Defining Factor to Response from Promising Melanoma Drug

CHICAGO — In examining why some advanced melanoma patients respond so well to the experimental immunotherapy MK-3475, while others have a less robust response, researchers…

Sign up